Experienced in Lung Metastases

Michel M. Van Den Heuvel

Nijmegen, GE, NL 
Experienced in Lung Metastases
Nijmegen, GE, NL 
OverviewLocationsClinical Research

Overview

Michel Van Den Heuvel practices in Nijmegen, Netherlands. Mr. Van Den Heuvel is rated as an Experienced expert by MediFind in the treatment of Lung Metastases. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Pleural Effusion, Tissue Biopsy, and Endoscopy.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Lung Metastases.

Gender
Male

Locations

Nijmegen, GE, Netherlands
Other Locations
Utrecht, UT, Netherlands
Amsterdam, NH, Netherlands
Medisch Spectrum Twente Enschede
Enschede, OV, Netherlands
Noordwest Ziekenhuisgroep
Alkmaar, NH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2025
Intervention Type: Drug, Radiation
Study Drug: Durvalumab
Study Phase: Phase 3
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Completed
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Terminated
Publish Date: May 13, 2022
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response
Enrollment Status: Completed
Publish Date: May 10, 2022
Intervention Type: Drug
Study Drug: Pemetrexed
Study Phase: Phase 4
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
Enrollment Status: Completed
Publish Date: January 10, 2022
Intervention Type: Drug, Diagnostic test
Study Drug: Avelumab
Study Phase: Phase 1
Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma
Olaparib Dose Escalating Trial in Patients Treated With Radiotherapy With or Without Daily Dose Cisplatin for Locally Advanced Non-small Cell Lung Carcinoma
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 6 Less Clinical Trials

148 Total Publications

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.
Journal: Clinical pharmacokinetics
Published: July 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Van Den Heuvel's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile